Research
Hormonal
HEC-CG115 reduced fasting blood glucose and glycated haemoglobin levels similar to those after semaglutide.
HEC-CG115 may provide effective glycaemic control for patients with type 2 diabetes.
StrongSupportsmedium confidence
HEC-CG115 (one dose every 3 days) reduced fasting blood glucose and glycated haemoglobin levels similar to those after semaglutide (once daily) at the same dose.
Why this rating
Based on the direct comparison of effects in animal models.
Source
Development of a novel <scp>Fc</scp> fusion protein dual glucagon‐like peptide‐1 and gastric inhibitory polypeptide receptor agonists
Peng Jiang et al. · Diabetes Obesity and Metabolism · 2023
DOI 10.1111/dom.15235
otherCited 3×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →